Sarah Djermoun, Audrey Reuter, Elisabeth Derollez, Christian Lesterlin, Sarah Bigot
{"title":"重编程靶向抗菌质粒(TAPs)以实现广泛的宿主抗菌活性","authors":"Sarah Djermoun, Audrey Reuter, Elisabeth Derollez, Christian Lesterlin, Sarah Bigot","doi":"10.1016/j.plasmid.2023.102680","DOIUrl":null,"url":null,"abstract":"<div><p>The emergence and spread of antimicrobial resistance results in antibiotic inefficiency against multidrug resistant bacterial strains. Alternative treatment to antibiotics must be investigated to fight bacterial infections and limit this global public health problem. We recently developed an innovative strategy based on mobilizable Targeted-Antibacterial-Plasmids (TAPs) that deliver CRISPR/Cas systems with strain-specific antibacterial activity, using the F plasmid conjugation machinery for transfer into the targeted strains. These TAPs were shown to specifically kill a variety of Enterobacteriaceae strains, including <em>E. coli</em> K12 and the pathogen strains EPEC, <em>Enterobacter cloacae</em> and <em>Citrobacter rodentium</em>. Here, we extend the host-range of TAPs using the RP4 plasmid conjugation system for their mobilization, thus allowing the targeting of <em>E. coli</em> but also phylogenetically distant species, including <em>Salmonella enterica</em> Thyphimurium, <em>Klebsiella pneumoniae</em>, <em>Vibrio cholerae</em>, and <em>Pseudomonas aeruginosa</em>. This work demonstrates the versatility of the TAP strategy and represents a significant step toward the development of non-antibiotic strain-specific antimicrobial treatments.</p></div>","PeriodicalId":49689,"journal":{"name":"Plasmid","volume":"126 ","pages":"Article 102680"},"PeriodicalIF":1.8000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Reprogramming Targeted-Antibacterial-Plasmids (TAPs) to achieve broad-host range antibacterial activity\",\"authors\":\"Sarah Djermoun, Audrey Reuter, Elisabeth Derollez, Christian Lesterlin, Sarah Bigot\",\"doi\":\"10.1016/j.plasmid.2023.102680\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The emergence and spread of antimicrobial resistance results in antibiotic inefficiency against multidrug resistant bacterial strains. Alternative treatment to antibiotics must be investigated to fight bacterial infections and limit this global public health problem. We recently developed an innovative strategy based on mobilizable Targeted-Antibacterial-Plasmids (TAPs) that deliver CRISPR/Cas systems with strain-specific antibacterial activity, using the F plasmid conjugation machinery for transfer into the targeted strains. These TAPs were shown to specifically kill a variety of Enterobacteriaceae strains, including <em>E. coli</em> K12 and the pathogen strains EPEC, <em>Enterobacter cloacae</em> and <em>Citrobacter rodentium</em>. Here, we extend the host-range of TAPs using the RP4 plasmid conjugation system for their mobilization, thus allowing the targeting of <em>E. coli</em> but also phylogenetically distant species, including <em>Salmonella enterica</em> Thyphimurium, <em>Klebsiella pneumoniae</em>, <em>Vibrio cholerae</em>, and <em>Pseudomonas aeruginosa</em>. This work demonstrates the versatility of the TAP strategy and represents a significant step toward the development of non-antibiotic strain-specific antimicrobial treatments.</p></div>\",\"PeriodicalId\":49689,\"journal\":{\"name\":\"Plasmid\",\"volume\":\"126 \",\"pages\":\"Article 102680\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Plasmid\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0147619X23000112\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plasmid","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147619X23000112","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
Reprogramming Targeted-Antibacterial-Plasmids (TAPs) to achieve broad-host range antibacterial activity
The emergence and spread of antimicrobial resistance results in antibiotic inefficiency against multidrug resistant bacterial strains. Alternative treatment to antibiotics must be investigated to fight bacterial infections and limit this global public health problem. We recently developed an innovative strategy based on mobilizable Targeted-Antibacterial-Plasmids (TAPs) that deliver CRISPR/Cas systems with strain-specific antibacterial activity, using the F plasmid conjugation machinery for transfer into the targeted strains. These TAPs were shown to specifically kill a variety of Enterobacteriaceae strains, including E. coli K12 and the pathogen strains EPEC, Enterobacter cloacae and Citrobacter rodentium. Here, we extend the host-range of TAPs using the RP4 plasmid conjugation system for their mobilization, thus allowing the targeting of E. coli but also phylogenetically distant species, including Salmonella enterica Thyphimurium, Klebsiella pneumoniae, Vibrio cholerae, and Pseudomonas aeruginosa. This work demonstrates the versatility of the TAP strategy and represents a significant step toward the development of non-antibiotic strain-specific antimicrobial treatments.
期刊介绍:
Plasmid publishes original research on genetic elements in all kingdoms of life with emphasis on maintenance, transmission and evolution of extrachromosomal elements. Objects of interest include plasmids, bacteriophages, mobile genetic elements, organelle DNA, and genomic and pathogenicity islands.